Exactly, J8. When Ledipisvir comes out, and gilead has an all...

Exactly, J8. When Ledipisvir comes out, and gilead has an all oral, non RIBA non interferon treatment, they will have an even bigger reason why not to budge until real competition comes out. Right now, benitec really has the potential edge, if proven to be pan-genotype, to pull the rug out from underneath gilead, and if that happens, benitec shareholders benefit, and patients hopefully will reap the benefit of cheaper and more options.

Until it's efficacy is known, and production cost determined, no one really knows what that price will be, that is true.